Silvergate Capitalの空売り状況は、投資家がSilvergate Capitalの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Silvergate Capital (OTC:SICLQ) 株価情報, 空売り情報

Silvergate Capital Corp is a provider of various financial infrastructure solutions and services. Its solutions and service offerings include Silvergate Exchange Network, Cash Management Solutions and Deposit Account Services. Its customers include U.S. exchanges and global investors in the digital currency industry. The company also provides financial services that include commercial banking, business lending, commercial and residential real estate lending, and mortgage warehouse lending.

5.375% PRF PERPETUAL USD 25 - Ser A 1/40th Int

SILVERGATE CPTL D/S PFD A by Silvergate Capital Corporation

Silvergate Capital Corp

WIIM

LEG stock has given up its prior loss. Leggett & Platt shares were trading lower after the company reported better-than-expected Q1 EPS results and raised its FY25 EPS guidance.

News

Management

ARHS

Arhaus Names Michael Lee As CFO, Effective May 12th, 2025

Amkor Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/04/b45051935/amkor-technology-reports-financial-results-for-the-first-quarter-2025"> from the quarter. </a>
The Details: Amkor reported quarterly earnings of nine cents per share, in line with the analyst consensus estimate. Quarterly revenue came in at $1.32 billion, which beat the $1.28 billion consensus estimate.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
&#8220;Amkor delivered first quarter results in line with expectations, with revenue of $1.32 billion and EPS of $0.09,&#8221; said Giel Rutten, Amkor&#8217;s CEO. 
&#8220;We are closely monitoring the evolving landscape with tariffs and trade regulations and potential impacts on our customers&#8217; supply chains. Our diversified global footprint and long-standing partnerships allow us to help our customers work through complexity and uncertainty,&#8221; Rutten added. 
Outlook: Amkor sees second-quarter earnings of between seven cents and 23 cents per share, versus the 15 cent estimate, and revenue in a range of $1.375 billion to $1.475 billion, versus the $1.33 billion estimate.  
AMKR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Amkor Technology stock was up 2.17% after-hours at $17.86 on Monday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

After-Hours Center

Movers

Tech

AMKR

Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates

General

ATOM

Atomera Incorporated Announces A Strategic Marketing Agreement With A Global Leader In Chip Fabrication Technology Aimed At Accelerating The Adoption Of Atomera's Mears Silicon Technology For Next-generation Technologies; Terms Not Disclosed

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 27.1%. Currently, NRG Energy has a market capitalization of $22.27 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $326.16 today based on a price of $109.36 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745873110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In NRG Energy 5 Years Ago Would Be Worth This Much Today

TVGN

Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Overweight rating and announces Price Target of $104.

Price Target

Initiation

Analyst Ratings

VKTX

Cantor Fitzgerald Initiates Coverage On Viking Therapeutics with Overweight Rating, Announces Price Target of $104

NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a look at some of the key details <a href="https://www.benzinga.com/pressreleases/25/04/g45052384/nxp-semiconductors-reports-first-quarter-2025-results-announces-management-transition">from the report</a>.
Q1 Earnings: NXP reported first-quarter revenue of $2.84 billion, in line with analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a>, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported first-quarter adjusted earnings of $2.64 per share, beating analyst estimates of $2.58 per share.
Total revenue in the first quarter was down 9% on a year-over-year basis. The company said it generated $565 million in cash flow from operations, as well as free cash flow of $427 in the quarter.
&#8220;NXP delivered quarterly revenue of&nbsp;$2.84 billion, in-line with the midpoint of&nbsp;guidance. NXP&#8217;s&nbsp;first-quarter&nbsp;results and&nbsp;guidance&nbsp;for the&nbsp;second quarter&nbsp;underpin a cautious optimism that NXP continues to effectively navigate through a challenging set of market conditions,&#8221; said Kurt Sievers, president and CEO of NXP.
&#8220;We are operating in a very uncertain environment influenced by tariffs with volatile direct and indirect effects. Considering these external factors, we are redoubling our efforts to manage what is in our direct control, enabling NXP to drive solid profitability and earnings.&#8221;
Related Link: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45038044/top-wall-street-forecasters-revamp-nxp-semiconductors-expectations-ahead-of-q1-earnings">Top Wall Street Forecasters Revamp NXP Semiconductors Expectations Ahead Of Q1 Earnings</a>
Outlook: NXP expects second-quarter revenue of $2.8 billion to $3 billion versus estimates of $2.87 billion. The company sees second-quarter adjusted earnings in the range of $2.46 to $2.86 per share versus estimates of $2.65 per share.
The quarterly figures and second-quarter guidance appear to be largely in line with estimates. Cautious commentary from executives as well as a CEO transition appear to be weighing on shares after the bell. 
NXP announced that Sievers intends to retire at the end of 2025. The board has unanimously approved Rafael Sotomayor to succeed Sievers. Sotomayor will take over as president and CEO in October following a transition period.
NXP executives will further discuss the quarter on a call with analysts and investors Tuesday morning at 8 a.m. ET.
NXPI Price Action: <a href="https://www.benzinga.com/quote/NXPI" target="_blank" rel="noreferrer noopener">NXP Semiconductors shares</a> were down 8.02% after-hours, trading at $180.50 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">How You&#8217;ll Know When Tariff Troubles Are Finally Over</a></li>
</ul>
Photo: Lukassek/Shutterstock.

Guidance

NXPI

NXP Semiconductors Reports Q1 Earnings: 'Very Uncertain' Operating Environment Tied To Tariffs, CEO Transition, Shares Fall

<ul>
<li>Reflects business philosophy of commercial success through patient accessibility</li>
<li>Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company's dedicated R&amp;D and manufacturing facility; no impact on shareholder equity</li>
</ul>
WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jSbvQBvaGIm4QLP6v08YeTss46FD6iNPmKu1voOrF5vXBpzNT7keXDuzL599zfMXevkmSVtVucFZru53B0ZvFw==">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. The forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Tevogen Reaffirms Its Top-Line Revenue Forecast For Its Oncology Pipeline, Projecting $1B In Revenue In Its Launch Year And A Cumulative 5-Year Estimate Of Between $10B-$14B

Earnings Beats

ALRS

Alerus Finl Q1 Adj. EPS $0.52 Beats $0.42 Estimate, Sales $68.83M Beat $66.16M Estimate

Biotech

ARTV

Artiva Biotherapeutics to Reveal Longer-term Phase 1/2 Data For AlloNK in Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At the ASGCT 28th Annual Meeting

COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) narrows FY2025 FFO guidance from $2.62-$2.70 to $2.63-$2.69 vs $2.66 analyst estimate..

COPT Defense Props Narrows FY2025 FFO Guidance from $2.62-$2.70 to $2.63-$2.69 vs $2.66 Est

COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) is looking for Q2 FFO of $0.65-$0.67 vs $0.67 analyst estimate..

COPT Defense Props Sees Q2 FFO $0.65-$0.67 vs $0.67 Est

COPT Defense (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 4.84 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $187.86 million which beat the analyst consensus estimate of $175.86 million by 6.82 percent. This is a 2.80 percent decrease over sales of $193.27 million the same period last year.

COPT Defense Q1 FFO $0.65, Inline, Sales $187.86M Beat $175.86M Estimate

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.64 by 20.31 percent. This is a 77.75 percent decrease over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $7.83 billion which beat the analyst consensus estimate of $7.23 billion by 8.29 percent. This is a 3.77 percent decrease over sales of $8.14 billion the same period last year.

Nucor Q1 Adj. EPS $0.77 Beats $0.64 Estimate, Sales $7.83B Beat $7.23B Estimate

ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.95) by 15.79 percent. This is a 25.23 percent increase over losses of $(1.07) per share from the same period last year.

ITOS

ITeos Therapeutics Q1 EPS $(0.80) Beats $(0.95) Estimate

ACET

Adicet Bio To Give Oral Presentation For Its Preclinical ADI-270 Data At The American Society Of Gene And Cell Therapy 28th Annual Meeting

Bitcoin (<a href="https://www.benzinga.com/quote/BTC-USD">BTC</a>) might not be digital gold due to its risky nature. But as an investment over the last 12 months, it's up 49% while the SPDR Gold Trust (<a href="https://www.benzinga.com/quote/GLD">GLD</a>) ETF is up 43%. Nasdaq is up around 8%. Looked at in that time frame, BTC is as good as gold, for real.
"While bitcoin continues to function as an ultra risk-on asset, paradoxically, the digital gold narrative has continued to gather strength," said Greg Waisman, Chief Operating Officer at Mercuryo, a fintech company headquartered in Canada.&nbsp;
"Bitcoin has displayed relative resilience against tariff concerns and a potential recession," he said, noting that BTC has outperformed tech stocks all year. "That might make Bitcoin seen by some as displaying characteristics more akin to a store of value such as gold," Waisman said.
The notion that Bitcoin was "as good as gold" began around 2021. Michael Novogratz, founding CEO of Galaxy Digital Holdings (<a href="https://www.benzinga.com/quote/BRPHF">BRPHF</a>), a crypto investment firm that trades on the Toronto Stock Exchange, <a href="https://www.goldmansachs.com/pdfs/insights/pages/crypto-a-new-asset-class-f/report.pdf?utm">said</a> at the time that "Bitcoin is a really convenient way to store value. The main reason everyone got into bitcoin is the same reason they got into gold—the current macro backdrop is tailor-made for it."
Novogratz later called it <a href="https://www.goldmansachs.com/insights/articles/from_briefings_18-feb-2021?utm">"digital gold"</a> during a Goldman Sachs event that same year. That theme has stuck around ever since.&nbsp;
"The digital gold label reflects Bitcoin's core proposition: scarcity, decentralization, and its role as a store of value," said Mithil Thakore, Co-Founder &amp; CEO at <a href="https://www.benzinga.com/quote/VELAR-USD">Velar</a>, a Dubai-based DeFi play.
If Bitcoin is to be likened as digital gold for its store of value, then it must be seen as the more rambunctious cousin to the yellow metal. Looked at over the last year and Bitcoin looks exactly like gold when compared to GLD. Looked at over five years and Bitcoin is a runaway train, far outpacing everything in the market, with the possible exception of Nvidia (<a href="https://www.benzinga.com/quote/NVDA">NVDA</a>) stocks. Over the last three months, Bitcoin is down 10.7%, but that's better than the Nasdaq. And it has also held its value more than Nvidia.
Gold Safer Bitcoin Since Trump, But Bitcoin Safer Bet Than The S&amp;P 500
Despite Bitcoin being beaten by gold during the recent volatility, it's done better than the S&amp;P 500. Investors lost more money holding the SPDR S&amp;P 500 (<a href="https://www.benzinga.com/quote/SPY">SPY</a>) than they lost in BTC.
In official circles, of course, Bitcoin is not digital gold. The Securities and Exchange Commission <a href="https://www.sec.gov/comments/sr-cboebzx-2021-019/srcboebzx2021019-8857582-239811.pdf?utm">makes it clear</a> to investors: don't get your wires crossed on this trade.&nbsp;
Unlike gold, Bitcoin is not a collateral currency. Central banks hold gold because it can be a ready source of foreign exchange, especially for dollars. Gold can also serve as a collateral to access dollars during a crisis. That's why gold has value because of its repeated historical pattern acting as insurance to access liquidity during times of extreme crisis. As of now, Bitcoin has yet to demonstrate the role as a collateral currency, let alone for central banks.
Earlier this month, Peter Schiff panned the idea of Bitcoin as a safe haven investment. He was mostly criticizing the Trump administration's plan to consider holding BTC in a strategic reserve fund.
"I mean, if it's digital gold, it should have something in common with gold. It should trade similarly to Gold. It should have some kind of positive correlation. It doesn't have any," Schiff <a href="https://www.benzinga.com/25/04/44580634/bitcoin-is-digital-risk-not-digital-gold-asserts-peter-schiff">said</a> during his YouTube podcast. He called it the "anti-gold."&nbsp;
"Bitcoin is more than just a passive hedge," said Thakore. "Unlike gold, which sits in vaults, Bitcoin is programmable and forms the backbone of a new financial system." At Velar, Thakore said he is saying a shift from passive holding of Bitcoin in digital wallets, to active utility as a currency.&nbsp;
"Yes, Bitcoin is way more volatile than gold will ever be, but that volatility also reflects its growth phase," Thakore said. Gold has been around for thousands of years.&nbsp; Bitcoin was created in 2009. "We're witnessing the monetization of the number one digital asset in real time," he said.&nbsp; "In that sense, Bitcoin is gold with a built-in accelerator."
Disclosure: The writer of this article is a Bitcoin investor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Opinion

Bitcoin Might Not Be As Good As Gold Yet, But This Year, It Sure Is Acting Like It

Cellectis (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN&#xAE;-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans.

CLLS

Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) ("the Company"), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.
Oral Presentation Details:
Title: Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model Session: AAV Preclinical and Proof-of-Concept Studies Date and Time: Saturday, May 17, 2025, 9:15 a.m. – 9:30 a.m. CT Location: NOLA Theater A
The presentation will be available via the <a href="https://www.globenewswire.com/Tracker?data=aacUCQgF_Oqe0d8e_y3hmsG1Yc1wJ8J7vtDGrOFywijpE8bvkVPkvuBFk2XlW5vg7tSmk1RCOaeYE2GPEfH0QP9VxkDuoOvEvNpyCBVlpXesQo6kwqP-UmcEIaAmBw0khOcq05KG28BH3sebErxYrKb8bPbMDb5NILxzEUHB5dc=">Presentations &amp; Publications</a> section of the Fractyl website once it concludes on May 17, 2025. &nbsp;

GUTS

Fractyl Health Announces It Will Present Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform At American Society Of Gene And Cell Therapy 2025 Annual Meeting May 13-17, 2025, In New Orleans, Louisiana.

Comments

Silvergate Capital

空売り

Silvergate Capital (OTC:SICLQ) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル